MPE Newsletter

View this email in your browser
MPE activities

17th International Myeloma Workshop is about to kick-off in Boston, USA

Led by International Myeloma Society (IMS), the 17th International Myeloma Workshop (IMW) will be held in Boston, USA, from 12 to 15 September. Myeloma Patients Europe (MPE) will be attending this important myeloma scientific congress and will regularly post updates from the key scientific and clinical sessions on our communications channels.

Survey on myeloma patient information needs in 12 countries

Myeloma Patients Europe (MPE) has launched a survey for European myeloma patients to understand their information needs. If you are a myeloma patient who has received at least one prior treatment or is currently on their first treatment, MPE would be very grateful if you would take the time to complete the survey. The survey has been developed in collaboration with the pharmaceutical company Amgen and will be run in 12 European countries: Austria, Finland, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Sweden, Switzerland and the UK. You can find the country-specific survey links and tranlations in all relevant languages in the link below.

MPE member's activities

 

Austrian Myeloma Infoday

Our Austrian member, Multiples Myelom Selbsthilfe Oesterreich (MMSOe), is organising a myeloma infoday on 5 October in Austria. Updates in the treatment of myeloma or new treatments for relapsed or refractory myeloma will be some of the topics discussed. Find more information in the link below.
 

 

Myeloma news

 

Elotuzumab plus pomalidomide and dexamethasone approved for relapsed and refractory myeloma
 

European Commission (EC) has approved elotuzumab –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.
 
Read more…

Positive data of belantamab mafodotin in relapsed multiple myeloma
 

DREAMM-2, the pivotal open-label, randomised study of two doses of belantamab mafodotin has reported a clinically meaningful overall response rate (ORR) in relapsed myeloma patients. The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate
 

If you are an MPE member and you would like to share your activities in this e-bulleting, please contact Ana Vallejo: vallejo@mpeurope.org.

17th International Myeloma Workshop
Boston, 12-15 September
The 17th International Myeloma Workshop under the auspices of the International Myeloma Society (IMS) is devoted to fostering scientific and clinical exchange on the latest breakthroughs in multiple myeloma and related plasma cell disorders
More information

ESMO 2019
Barcelona, 27 Sept-1 Oct
The European Society for Medical Oncology (ESMO) Congress is an opportunity for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together in Europe and to learn about the latest advances in oncology and translate science into better cancer patient care.
More information

ASH 2019 Annual Meeting
Orlando, 7-10 December
American Society of Hematology (ASH) Annual meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
More information
 

Would you like to get involved in MPE patient-focused activities and research? Find more information in this link and complete the form
 
Copyright © 2019 Myeloma Patients Europe, All rights reserved.